Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer. by Kuppusamy, Hemalatha et al.
Inherited Polymorphisms in Hyaluronan Synthase 1
Predict Risk of Systemic B-Cell Malignancies but Not of
Breast Cancer
Hemalatha Kuppusamy1, Helga M. Ogmundsdottir2, Eva Baigorri1, Amanda Warkentin1,
Hlif Steingrimsdottir3, Vilhelmina Haraldsdottir3, Michael J. Mant1, John Mackey1, James B. Johnston4,
Sophia Adamia5, Andrew R. Belch1, Linda M. Pilarski1*
1University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada, 2University of Iceland, Reykjavik, Iceland, 3 Landspitali University Hospital, Reykjavik,
Iceland, 4Dept. of Hematology, Cancer Care Manitoba and the University of Manitoba, Winnipeg, Manitoba, Canada, 5Medical Oncology, Dana-Farber Cancer Institute,
Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
Genetic variations in the hyaluronan synthase 1 gene (HAS1) influence HAS1 aberrant splicing. HAS1 is aberrantly spliced in
malignant cells from multiple myeloma (MM) and Waldenstrom macroglobulinemia (WM), but not in their counterparts
from healthy donors. The presence of aberrant HAS1 splice variants predicts for poor survival in multiple myeloma (MM). We
evaluated the influence of inherited HAS1 single nucleotide polymorphisms (SNP) on the risk of having a systemic B cell
malignancy in 1414 individuals compromising 832 patients and 582 healthy controls, including familial analysis of an
Icelandic kindred. We sequenced HAS1 gene segments from 181 patients with MM, 98 with monoclonal gammopathy of
undetermined significance (MGUS), 72 with Waldenstrom macroglobulinemia (WM), 169 with chronic lymphocytic leukemia
(CLL), as well as 34 members of a monoclonal gammopathy-prone Icelandic family, 212 age-matched healthy donors and a
case-control cohort of 295 breast cancer patients with 353 healthy controls. Three linked single nucleotide polymorphisms
(SNP) in HAS1 intron3 are significantly associated with B-cell malignancies (range p= 0.007 to p= 1025), but not MGUS or
breast cancer, and predict risk in a 34 member Icelandic family (p = 0.005, Odds Ratio = 5.8 (OR)), a relatively homogeneous
cohort. In contrast, exon3 SNPs were not significantly different among the study groups. Pooled analyses showed a strong
association between the linked HAS1 intron3 SNPs and B-cell malignancies (OR = 1.78), but not for sporadic MGUS or for
breast cancer (OR,1.0). The minor allele genotypes of HAS1 SNPs are significantly more frequent in MM, WM, CLL and in
affected members of a monoclonal gammopathy-prone family than they are in breast cancer, sporadic MGUS or healthy
donors. These inherited changes may increase the risk for systemic B-cell malignancies but not for solid tumors.
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Introduction
Hyaluronan synthase 1 (HAS1) produces hyaluronan (HA), a
polysaccharide with complex biological effects [1]. Here, we
evaluated the influence of inherited HAS1 single nucleotide
polymorphisms (SNP) on the risk of having a systemic B cell
malignancy in 832 patients and 582 controls. Using targeted
sequencing of HAS1 SNPs to unequivocally genotype patient
populations and to identify potential low penetrance mutations, we
reduced the uncertainties associated with array screening and
genome-wide association studies. Herein, we show that three
HAS1 intron3 SNPs (rs11084110, rs11084109 and rs11669079)
are significantly more frequent in patients with systemic B-cell
malignancies or in members of a four-generation Icelandic kindred
affected by a monoclonal gammopathy-prone phenotype [2;3]
than in healthy donors, unaffected Icelandic family members or
patients with solid tumors. Overall, the study of 1414 subjects,
including 832 patients and 582 healthy controls, suggests that
these inherited changes may predispose to the development of
systemic B cell malignancies (multiple myeloma, chronic lympho-
cytic leukemia or Waldenstrom macroglobulinemia), but do not
predispose to sporadic monoclonal gammopathy of undetermined
significance (MGUS) or breast cancer.
Hyaluronan synthase 1 products, encoded by the HAS1 gene,
appear central to the events giving rise to B cell malignancies and
to disease progression [1]. HAS1 is aberrantly spliced in malignant
cells from multiple myeloma (MM) and Waldenstrom macroglob-
ulinemia (WM), but not in their counterparts from healthy donors
[4]. HA produced by HAS1 splice variants is likely to contribute to
mitotic abnormalities and to malignant spread/migration [1;4;5],
suggesting that aberrant splicing may be an important contributor
to systemic B cell malignancies. The presence of the aberrant
HAS1Vb intronic splice variant correlated with poor survival in
MM patients [4]. In transfectants, a HAS1 variant is oncogenic
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in vivo and in vitro [6], possibly resulting from induction of
chromosomal instability by aberrant intracellular HA and
promotion of malignant spread by extracellular HA [1]. Inherited
single nucleotide polymorphisms (SNPs) and mutational hotspots
in HAS1 exon3 through intron3 influence HAS1 pre-mRNA
splicing [7;8]. A major strength of this study is that we have
analyzed the HAS1 polymorphisms in five different disease cohorts
and two geographically independent populations (western Cana-
dians and the Icelandic kindred) with their appropriate healthy
donor control groups. This is the first report that risk for B-cell
malignancies and an inherited monoclonal gammopathy-prone
phenotype is directly correlated with intronic HAS1 SNPs, likely by
promoting aberrant HAS1 splicing.
Methods
Study Subjects
Patients with MM, WM or sporadic MGUS were seen at the
Cross Cancer Institute and the University of Alberta hospital
(Edmonton, AB), and diagnosed according to recommended
guidelines [9;10] CLL cells were obtained from the Manitoba
CLL Tumor Bank at the Manitoba Institute of Cell Biology. This
study was approved by Ethics Review Boards from the University
of Alberta, the University of Manitoba, the University of Iceland
and Alberta Health Services. Subjects provided written informed
consent. Approval for the familial studies was from the Icelandic
National Bioethics Committee, license number 8-107-S1, Data
Protection Authority: 20096080676. We sequenced DNA from
1,414 individuals (Table 1): this includes a total of 582 healthy
control subjects. Controls for B-cell malignancies were 212
anonymous age-matched donors. For breast cancer, 295 anony-
mous blood samples from patients and 353 matched healthy
controls were from the Alberta Research Tumor Bank. For all
groups, peripheral blood was taken at the time of diagnosis or at
follow-up. We genotyped PB from 34 members from four
generations of a monoclonal gammopathy-prone Icelandic family
[2;3]. Family members were of both genders; ‘‘controls’’ were the
unaffected family members. Affected family members were those
with MGUS, MM, WM or a hyper-Ig phenotype. Both the
Icelandic kindred and the patients from western Canada are
predominantly of Caucasian descent.
Genotyping and Analysis
Peripheral blood mononuclear cells were isolated and genomic
DNA was purified from 56106 PBMCs using QIAamp DNA
Blood mini kit (QIAGEN). For two Icelandic samples, DNA was
isolated from paraffin-embedded tissue, and amplified with whole
genome amplification (WGA). Primers were designed based on the
consensus human HAS1 NCBI gene coding sequence (NCBI
Reference Sequence: NC_000019.10) (Table S1 in File S1). A
HAS1 gene segment from exon3 to intron3 inclusive was amplified
in a 50 ml PCR reaction mix (Table S2 in File S1).
Quality Control
To ensure the genotyping results were accurate, we randomly
re-sequenced selected DNA samples. For high fidelity Taq DNA
polymerase, an enzyme lot was used with an error rate confirmed
by us to be 3.061024 error/bp. DNA sequencing profiles were
analyzed with SeqScape V2.1 for base-calling software/alignment
(Applied Biosystems (ABI), CA), confirmed manually by visual
inspection of the sequencing profile.
Subcloning and Direct Sequencing
PCR-amplified gene segments were sequenced using two
methods: 1) by subcloning in an appropriate vector or 2) by direct
sequencing of double or single stranded PCR products. For each
patient whose PCR products were subcloned, a minimum of 8
subclones were sequenced in both directions. If a given base was
present in all subclones, the two alleles were considered to be
homozygous. Heterozygosity was defined as having at least 1/8
subclones with the second allele. 40% of samples were sequenced
using plasmid subcloning and 60% were sequenced directly using
Big-Dye 3.1 (ABI) on the ABI3130xl DNA analysis system.
Obtained sequences were compared to the NCBI HAS1 reference
sequence (NC_000019.10).
Statistical Analysis
Hardy-Weinberg equilibrium (HWE) tests were performed for
each SNP. We assessed for deviations from HWE using the chi-
square test, with 5 degrees of freedom. The SNPs were only
considered for further analysis if the allele frequency conformed to
HWE expectation. This ensures that any loss of heterozygosity
that might be present in malignant cells is excluded from analysis
[11]. The difference in genotype and allele frequencies between
patients and healthy controls were analyzed by the Fischer exact
test: probability values (P values) of ,0.05 were considered
statistically significant. The HAS1 alleles designated as ‘‘minor’’ by
NCBI are the most frequent in the populations studied, with the
exception of the Icelandic kindred, but we followed the accepted
NCBI dbSNP database convention for naming.
Unconditional logistic regression analysis was performed to
obtain odds ratios (OR) and 95% confidence interval (CI) to
independently estimate relative risks for each SNP, using Statistical
Analysis Software (SAS institute). The independent cohorts were
Table 1. Characteristics of study participants (N= 1414).
Study Group No of samples Age Range Sample type
MGUS 98 44–87 (n = 67) PB
MM 181 46–91 (n = 66) PB
CLL 169 37–82 (n = 66) Purified malignant B cells
WM 72 50–82 (n = 66) PB
Controls 212 Above 60 PB
Icelandic kindred 34 4 generations PB
Breast cancer cases 295 29–80 PB
Breast cancer Controls 353 29–80
doi:10.1371/journal.pone.0100691.t001
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then combined for Forest plot analysis without any weightage.
They show the amount of variation between the studies and an
estimate of the overall result. Linkage disequilibrium analysis was
done using Haploview bioinformatic software (MIT/Harvard Broad
Institute). Linked SNPs (rs11084110, rs11084109 and rs11669079)
show strong LD patterns in all the four case groups and D’ values
are above 90. In contrast, the exon3 SNPs (rs61736495,
rs11084111) are in equilibrium; only rs11084111 was present in
the Icelandic kindred.
Results
HAS1 Polymorphisms
HAS1 gene segments from 1414 individuals were sequenced
(Table 1). In the dbSNP database, ten HAS1 SNPs occur in the
region sequenced (Figure 1, Table-S3 in File S1); of these only five
met the Hardy-Weinberg Equilibrium criterion of p.0.05; these
were two SNPs in exon 3 and three SNPs in intron 3.
HAS1 Genotype and Minor Allele Frequencies in an
Icelandic Kindred
We analyzed 34 members of an Icelandic family predisposed to
monoclonal gammopathies, including IgM gammopathy, CLL,
MM and WM [2;3] (Table 2). Twelve family members showed
increased production of immunoglobulin in vitro, referred to as
hyper-responders [3]. The 12 hyper-responders plus two family
members diagnosed MGUS, two with WM and one with MM (a
total of 17 family members) were termed ‘‘affected’’ family
members. Controls were 17 unaffected family members who
lacked any evidence of monoclonal gammopathies and did not
have a hyper-responder phenotype. In the Icelandic kindred, the
frequencies of the linked intron3 SNPs (rs11084110, rs11084109
and rs11669079) for affected members were significantly different
from those of unaffected members (genotype frequencies p= 0.007
for the intron3 SNPs). In contrast, the exon3 SNP rs11084111 is
not significantly different between affected and unaffected family
members, providing an internal control. The minor allele
frequency for the linked intron3 SNPs was 0.74 for affected and
0.32 for unaffected family members (Table 2), a highly significant
difference (p = 0.0005).
Figure 1. A schematic diagram of HAS1 gene locus in
chromosome 19q13. Some parts of Figure 1 were created using
Gene Window Software http://genewindow.nci.nih.gov/.
doi:10.1371/journal.pone.0100691.g001
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Minor Allele Frequencies (MAF) for Study Cohorts
The allele frequencies for patients and their respective control
groups were determined (Table 3). For HAS1 exon3 SNPs the
allele distribution between the cancer groups and their controls are
not significantly different. In contrast however, the linked HAS1
intron3 SNPs, the MAF are significantly higher in CLL and WM
than they are in the age-matched control group. For all of the
intron3 SNPs, the MAF is 0.80 for CLL and 0.81 for WM
compared to 0.75 for MM and 0.63 for sporadic MGUS. For
MM, sporadic MGUS and the breast cancer group (0.71), the
MAFs for the linked HAS1 intron3 SNPs are not significantly
different from their respective control groups. For HAS1 exon3
SNPs the allele distribution between the cancer groups and their
controls are not significantly different.
Association between HAS1 SNP Genotypes and B-cell
Malignancies
Two-tailed unconditional logistic regression was used to
determine the effect of HAS1 SNP genotypes on the presumptive
risk of B-cell malignancy (Table 4). No assumptions were made
about the effect of the SNPs prior to analysis. Odds ratios (OR)
measure the impact of a given HAS1 SNP on the risk of having a
B-cell malignancy (Table 4). Each cancer group was compared to
its control group.
As compared to the healthy controls, for the linked HAS1
intron3 SNPs, the genotypes having the ‘‘minor’’ allele were each
associated with an increased risk of B-cell malignancy but not of
MGUS, perhaps because only 1–2% of sporadic MGUS transform
to MM. For the exon 3 SNPs, there was no association between
HAS1 SNP genotype and B-cell malignancies or MGUS. The
intronic HAS1 SNP rs11084110 was associated with 1.5-fold
increase in the risk for MM (OR=1.53; p = 0.008). The OR was
2.0 for CLL and 2.1 for WM, both of which have a higher familial
incidence than does MM. Similar results were observed for the
other two intronic SNPs (Table 4). To determine whether or not
the linkage between intronic HAS1 SNPs and risk was restricted to
B cell malignancies, we also evaluated a cohort of breast cancer
patients. There was no difference between breast cancer patients
and their matched healthy control group, indicating a lack of
association with HAS1 SNPs (Table 5). Comparison of the B-cell
cancer group (MM, CLL and WM) with the breast cancer subjects
shows that for all the three linked SNPs, the systemic B cell
malignances have a significantly greater association than does
breast cancer (p$0.01). Thus, the solid tumor group and its
controls provide a negative control for the patient groups
harboring systemic B-cell malignancies. Our findings showed that
the linked HAS1 intron3 SNPs, had a significant association with
all B-cell malignancies studied (Table 4), an association that
appears restricted to B-cell malignancies.
Pooled Association Analysis
For increased power to demonstrate a relationship between
HAS1 SNPs and the risk of a B-cell malignancy, three case cohorts
(MM, CLL and WM) were pooled for analysis (Figure 2). When
MM, CLL and WM were evaluated as a single group in
comparison with the healthy control group, we found a significant
association between the linked HAS1 intron3 SNPs, and the risk of
systemic B-cell malignancy. For the three HAS1 intronic SNPs
(OR=1.78–1.80; p,0.001), the overall risk was 1.78 (Figure 2, left
column of panels) for the group of B cell malignancies. For the
Icelandic family members the overall risk was 5.8; no such risk was
seen for breast cancer or for the cohort of patients with sporadic
MGUS (OR=0.85 or 0.88, respectively) (Figure 2, right column
of panels).
Discussion
Extensive inherited and acquired mutations characterize HAS1
in patients with B-cell malignancies [8]. HAS1 overexpression has
also been reported for some solid tumors, including prostate,
ovarian and bladder cancers [1;12–14]. To avoid the uncertainties
inherent in genome-wide association studies, we sought suscepti-
bility polymorphisms in a candidate gene, HAS1, based on the
biology of the gene in cancer patients. By sequencing in 832
patients and 582 healthy controls (a total of 1,414 individuals) a
segment of the HAS1 gene known to influence aberrant HAS1
splicing [7;8], we show that the presence of HAS1 SNPs is strongly
associated with the diagnosis of a systemic B-cell malignancy
(range of p = 0.005 to p= 1025, OR=1.5 ranging to OR=2.1,
overall risk = 1.78), but not with a solid tumor. For the Icelandic
family members the overall risk was 5.8; no such risk was seen for
breast cancer or for the cohort of patients with sporadic MGUS
that have no known familial predisposition. The observation that
HAS1 intronic SNPs do not confer risk to patients with sporadic
MGUS likely reflects the fact that only a very small proportion are
at risk of transformation to frank malignant disease. It seems likely
from the Icelandic familial analysis that if biomarkers were
available that preferentially select for only those MGUS that will
transform to frank malignancy, a risk association would become
detectable. In the Icelandic family kindred, HAS1 SNPs were more
frequent in affected members (those with monoclonal gammop-
athies or hype-responder phenotype) than in unaffected family
members (p = .0005), confirming the association with risk in a four
generation family having a shared genetic heritage.
The increased risk associated with minor allele genotypes in
HAS1 intron 3, as first shown here, is supported by our previous
work [1;8;15]. In some blood cancer patients, HAS1 is a
hypermutated gene [8] that undergoes aberrant splicing to
generate splice variants that correlate with poor survival [4].
In vitro mutagenesis of HAS1 intron3 alters HAS1 splicing patterns,
causing transfectants to acquire the splicing pattern seen in MM
patients[7;8]. In silico and in vitro mutagenesis analyses predict that
HAS1 intron3 plays a central role in clinically relevant splice site
selection and consequent aberrant intronic splicing of HAS1 [7;8].
Intronic SNPs can have a functional impact by affecting gene
regulation and splicing mechanisms [16–18], confirming that
intronic SNPs have a potentially strong influence on oncogenic
events. In MM and WM, HAS1 genetic variations are distributed
in or near splicing elements [8;15] and can direct aberrant splicing
of HAS1 [7;8]. In transfected cells, the properties of aberrant
HAS1 variants are dominant over those of the normally expressed
HAS1 full length form [6].
The independent Icelandic kindred is a small but relatively
homogeneous population with a common ancestry. Affected
family members exhibit hyper-Ig synthesis in vitro and some have
MGUS, WM or MM. The linked HAS1 intron3 SNP alleles and
genotypes of affected members, but not an exon3 SNP, were
significantly different from those of unaffected members (genotype
frequencies p = 0.007, allele frequencies p = 0.0005).
In the pooled analysis of SNP genotypes for all patient and
control groups, the odds ratio for B cell malignancy (ORtrend) was
1.78 and for affected Icelandic family members, OR was 5.8.
These odds ratios, especially when considered in the context of the
familial analysis, suggest minimal or no influence of cryptic
population stratification. Risk predictions may be directly corre-
lated with the identified SNPs, or may result from unknown
Risk Assessment for Systemic B-Cell Malignancies
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mutation(s) outside the sequenced region but in linkage disequi-
librium with the detected SNPs. The OR for breast cancer patients
and MGUS did not differ from unity, suggesting that the increased
risk conferred by HAS1 SNPs is selective for systemic B-cell
malignancies.
Family members of patients with MGUS or MM have a two-
three-fold higher risk of developing MGUS and multiple myeloma
[19–22]. CLL and WM include both sporadic and familial forms
of the disease [23–26]. Inherited polymorphisms are associated
with both CLL and WM [15;25;27–31], and a strongly recurrent
somatic mutation with WM [32]. The odds ratios found here for
CLL and WM were considerably more pronounced than those
found for MM which appears to have less familial influence.
However, this work demonstrates for the first time that an
increased frequency of HAS1 intron3 SNPs is common among all
three systemic B-cell malignancies, possibly indicating shared
genetic predispositions that culminate in malignant transformation
of B-cells.
We employed sequencing for this study because it provides for
unequivocal allele calling in each patient, as well as identification
Figure 2. Forest plots of three linked SNPs in B-cell Malignancies, the Icelandic kindred, breast cancer and MGUS. The left column of
three panels show the odds ratios of B cell malignancy for the three linked intronic HAS1 SNPs. The OR denotes the odds of having the minor allele as
assessed by genotype. The X-axis corresponds to odds ratio. The horizontal line represents 95% confidence interval. Each box represents the OR point
estimate. The diamond represents the odds ratios obtained from pooled analysis with 95% confidence interval. Each group is compared to the
appropriate control group. The right column of three panels show odds ratios for the Icelandic kindred, MGUS and breast cancer; each individual
group is compared to its own control group as indicated in results. The cumulative risks were not estimated for these last three groups as they are
unrelated to each other. These plots show that there were no associations of risk with the three linked SNPs for sporadic MGUS or breast cancer.
There was a very strong association of the minor allele with risk for the B cell malignancies (pooled OR= 1.78) and the Icelandic Kindred (OR= 5.8).
Note difference in scale values between panels in the two columns.
doi:10.1371/journal.pone.0100691.g002
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of any closely linked rare mutations that might influence risk. An
advantage in SNP detection by direct DNA sequencing is the
complete information it yields, including haplotype relationships.
Recent literature supports our approach [33] and emphasizes the
use of sequencing to detect direct associations between disease and
casual SNPs [34]. Our analysis was restricted to polymorphisms in
HAS1 exon3 and intron3, a mutation-rich region that is involved
in aberrant splicing of HAS1 exons and introns [7;8]. Our work
suggests that the three linked HAS1 intronic SNPs may predispose
to aberrant splicing, or are in linkage disequilibrium with a
causative functional variant located outside exon3 and intron3 of
HAS1. This study provides strong evidence to support the
hypothesis that HAS1 contributes to a genetic risk of B-cell
malignancy.
In conclusion, our findings suggest that genetic variants in HAS1
are associated with risk of B-cell malignancy in MM, CLL and
WM. Because the HAS1 intron3 SNPs are present at significantly
higher frequencies in individuals who have developed a systemic
B-cell cancer, these results suggest that intronic HAS1 SNPs
predispose to systemic B-cell cancers and as inherited character-
istics may thus act at an early stage of oncogenesis. Although
multiple genes are certainly involved, this work supports the idea
that HAS1 intron3 SNPs have a strong impact on molecular
events, particularly on aberrant HAS1 pre-mRNA splicing events
that contribute to the malignant phenotype in B-cell cancers.
Molecular therapy to target this region of HAS1 warrants
evaluation.
Supporting Information
File S1 Suppporting Tables. Table 1, Primer sequences used
for PCR or sequencing reactions. Table S2, Components of PCR
mixture. Table S3, HAS1 SNPs observed in this study.
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